Boston Scientific Corporation $BSX Shares Bought by Peak Financial Advisors LLC

Peak Financial Advisors LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 191.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,470 shares of the medical equipment provider’s stock after buying an additional 12,788 shares during the period. Peak Financial Advisors LLC’s holdings in Boston Scientific were worth $1,856,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. CreativeOne Wealth LLC lifted its holdings in Boston Scientific by 65.0% in the 2nd quarter. CreativeOne Wealth LLC now owns 12,667 shares of the medical equipment provider’s stock valued at $1,361,000 after acquiring an additional 4,988 shares during the last quarter. RiverFront Investment Group LLC boosted its position in shares of Boston Scientific by 9.7% during the 2nd quarter. RiverFront Investment Group LLC now owns 5,904 shares of the medical equipment provider’s stock valued at $634,000 after purchasing an additional 524 shares in the last quarter. Laurel Wealth Advisors LLC boosted its position in shares of Boston Scientific by 25,858.3% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 3,115 shares of the medical equipment provider’s stock valued at $335,000 after purchasing an additional 3,103 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of Boston Scientific by 17.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 42,032 shares of the medical equipment provider’s stock worth $4,515,000 after purchasing an additional 6,199 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on BSX. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Citigroup reduced their price objective on Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Finally, UBS Group decreased their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $106.27.

Boston Scientific Stock Performance

Boston Scientific stock opened at $69.70 on Thursday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The firm’s 50 day simple moving average is $78.22 and its 200-day simple moving average is $91.25. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market cap of $103.59 billion, a P/E ratio of 35.93, a price-to-earnings-growth ratio of 1.05 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis pieces argue BSX may be due for a rebound and potential rating upside, which can attract buyers hunting a recovery after the pullback. Article Title
• Positive Sentiment: Commentary framing the recent decline as a buying opportunity — bullish theses and newsletter coverage are drawing attention from value/turnaround investors. Article Title
• Positive Sentiment: Independent bullish write-ups (summarizing growth prospects and valuation) are circulating and may be supporting dip-buying. Article Title
• Neutral Sentiment: Erste Group marginally trimmed its FY2027 EPS forecast (from $3.92 to $3.91) — a tiny cut that is unlikely to materially change earnings expectations. (Research note issued March 24)
• Neutral Sentiment: Healthcare-sector news (e.g., recognition of smaller device companies for innovation) is present but not directly tied to Boston Scientific’s fundamentals. Article Title
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in a securities class action covering the July 23, 2025–Feb 3, 2026 period; the wave of filings (Rosen, Pomerantz, Levi & Korsinsky, Faruqi, Glancy, Robbins Geller, Bernstein, etc.) increases litigation uncertainty and potential legal costs. Representative notices: Rosen (Newsfile), Levi & Korsinsky (GlobeNewswire), Faruqi & Faruqi. Rosen Notice Levi & Korsinsky Bronstein Notice

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.